Skip to main content

Coloma Jason V's Form 4 filing

Maze Therapeutics, Inc.MAZE · filed May 18, 2026

Accession no.
0001676170-26-000004
Filed
May 18, 2026
Trade date
May 15, 2026
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $50.4K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Coloma Jason VCIK 0001676170Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2026Common StockSSaleDisposed−1,822$26.00−$47,372381,073Indirect
May 15, 2026Common StockSSaleDisposed−116$26.00−$3,01631,001Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

The securities reported on this Form 4 as attributable to the Family Trust and the Irrevocable Trust were incorrectly reported on the reporting person's Form 3 as directly held by the reporting person. This Form 4 corrects his Form 3 and restates the attribution of his holdings. All prior Section 16 reports filed on behalf of the reporting person should be understood to incorporate this correction.

Read the full filing on SEC EDGAR (opens in a new tab)